Related Experiment Videos
D-CECaT: a breakthrough for patients with neuroblastoma
A Donfrancesco1, G Deb, A Angioni
1Oncology Service, Ospedale Pediatrico Bambino Gesu, Rome, Italy.
Anti-Cancer Drugs
|June 1, 1993
Summary
A new chemotherapy regimen, D-CECaT, incorporating deferoxamine, shows effectiveness in treating advanced neuroblastoma (NB) and primitive neuroectodermal tumors (PNET), offering hope for improved patient outcomes.
Area of Science:
- Oncology
- Pediatric Oncology
- Pharmacology
Background:
- Advanced neuroblastoma (NB) and primitive neuroectodermal tumors (PNET) have high relapse rates after standard chemotherapy.
- Novel therapeutic strategies are needed to improve treatment efficacy and reduce relapse in these pediatric cancers.
Purpose of the Study:
- To evaluate a novel chemotherapy regimen, D-CECaT, for advanced NB and PNET.
- To assess the efficacy and safety of incorporating the iron chelator deferoxamine to sensitize cancer cells to chemotherapy.
Main Methods:
- The D-CECaT regimen included deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa administered over specific days.
- Twenty-three patients with advanced NB and two with PNET were enrolled between October 1989 and May 1992.
- Treatment responses and adverse events were meticulously recorded.
Main Results:
- Complete response (CR) rates were observed in all previously untreated Stage III NB patients (6/6) and Stage IV NB patients (9/11).
- CR was also achieved in Stage IV PNET patients (2/2).
- Median survival for newly diagnosed patients was 22+ months, with some patients achieving long-term remission.
Conclusions:
- The D-CECaT regimen demonstrates significant initial cytoreductive efficacy in advanced stage NB/PNET patients.
- Further studies with more patients are warranted to establish D-CECaT as an alternative to autologous bone marrow transplantation.